{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:04:00Z","timestamp":1790193840112,"version":"4.1.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Breast cancer is the most common malignant tumor among women worldwide, with an estimated 2.3 million new cases and nearly 670,000 deaths reported in 2022. The absence of hormone receptors and HER2\u00a0in triple-negative breast cancer (TNBC) reduces therapeutic options, contributing to a poorer prognosis. Tumor-infiltrating lymphocytes (TILs) are cells present in the tumor microenvironment, associated with a better prognosis and potentially playing a role in patient stratification and therapeutic management in the future. This protocol aims to assess the prognostic value of TILs in the survival of patients with TNBC, as well as their relationship with disease recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Comprehensive search will be conducted in the following databases: PubMed, Embase, Lilacs, Web of Science, Scopus, SciELO, ScienceDirect, and the Cochrane Library. The search will include cohort, case-control, and clinical trials studies that approach the prognostic value of TILs in TNBC and their role in optimizing treatment strategies, and no language restrictions. Two independent reviewers will select articles based on predefined inclusion and exclusion criteria, extract data, and assess the risk of bias using the QUIPS tool. Data synthesis will be conducted using the \u201cmeta\u201d package in R software, version 4.3.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This systematic review will synthesize current evidence on the prognostic significance of TILs in triple-negative breast cancer and their association with patient survival and disease recurrence. The findings may contribute to a better understanding of TILs as potential biomarkers for prognosis and guide future therapeutic strategies in TNBC management.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Review registration:<\/jats:bold>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/CRD42024568600\" xlink:type=\"simple\">CRD42024568600<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0342085","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:31:29Z","timestamp":1778607089000},"page":"e0342085","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of tumor-infiltrating lymphocytes as prognostic factor in triple-negative breast cancer: A protocol of systematic review and meta-analysis"],"prefix":"10.1371","volume":"21","author":[{"given":"Luciana Carla Martins de","family":"Aquino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1845-3729","authenticated-orcid":true,"given":"Elisandra Inara Silva","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana Maria Ferreira","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edilmar de Moura","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayane Cristine Alves","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleyton Santos de","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-5119","authenticated-orcid":true,"given":"Ana Katherine","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"pone.0342085.ref001","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3390\/cancers14102569","article-title":"Breast cancer\u2014epidemiology, classification, pathogenesis and treatment (review of literature)","volume":"14","author":"B Smolarz","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0342085.ref002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2159-8290.CD-22-0475","article-title":"The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes","volume":"13","author":"SS Onkar","year":"2023","journal-title":"Cancer Discov"},{"issue":"1130","key":"pone.0342085.ref003","doi-asserted-by":"crossref","first-page":"20211033","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"L Wilkinson","year":"2022","journal-title":"Br J Radiol"},{"issue":"3","key":"pone.0342085.ref004","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"H Sung","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"pone.0342085.ref005","article-title":"Diretrizes para detec\u00e7\u00e3o precoce do c\u00e2ncer de mama no Brasil. II - Novas recomenda\u00e7\u00f5es nacionais, principais evid\u00eancias e controv\u00e9rsias","volume":"34","author":"A Migowski","year":"2018","journal-title":"Cad Saude Publica"},{"key":"pone.0342085.ref006","author":"Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva (INCA)","year":"2020"},{"key":"pone.0342085.ref007","volume-title":"Estimativa 2023: Incid\u00eancia de c\u00e2ncer no Brasil","author":"Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva (INCA)","year":"2022"},{"key":"pone.0342085.ref008","first-page":"1","article-title":"Are global breast cancer incidence and mortality patterns related to country-specific economic development and prevention strategies?","volume":"71","author":"M Bellanger","year":"2018","journal-title":"J Glob Oncol"},{"issue":"8","key":"pone.0342085.ref009","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s13059-014-0431-1","article-title":"Genome-driven integrated classification of breast cancer validated in over 7,500 samples","volume":"15","author":"HR Ali","year":"2014","journal-title":"Genome Biol"},{"key":"pone.0342085.ref010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.36255\/exon-publications-breast-cancer-subtypes","article-title":"Subtypes of Breast Cancer.","volume-title":"Breast Cancer","author":"E Orrantia-Borunda","year":"2022"},{"key":"pone.0342085.ref011","volume-title":"Breast Tumours: WHO Classification of Tumours","author":"WHO","year":"2019"},{"issue":"21","key":"pone.0342085.ref012","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.3390\/cancers13215350","article-title":"Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (lncRNA) Transcriptomes Identifies Novel Diagnostic lncRNA Panel for Triple-Negative Breast Cancer","volume":"13","author":"H Shaath","year":"2021","journal-title":"Cancers (Basel)"},{"key":"pone.0342085.ref013","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cpet.2018.02.004","article-title":"Molecular classification of breast cancer","volume":"13","author":"E Provenzano","year":"2018","journal-title":"PET Clin"},{"key":"pone.0342085.ref014","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.soc.2017.08.005","article-title":"Molecular subtypes and local-regional control of breast cancer","volume":"27","author":"SM Fragomeni","year":"2018","journal-title":"Surg Oncol Clin N Am"},{"issue":"13","key":"pone.0342085.ref015","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.3390\/ijms21134579","article-title":"Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives","volume":"21","author":"S Cocco","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"9","key":"pone.0342085.ref016","doi-asserted-by":"crossref","first-page":"731","DOI":"10.20892\/j.issn.2095-3941.2024.0222","article-title":"Evolving molecular subtyping of breast cancer advances precision treatment","volume":"21","author":"R Shan","year":"2024","journal-title":"Cancer Biol Med"},{"issue":"2","key":"pone.0342085.ref017","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10555-021-09968-0","article-title":"Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer","volume":"40","author":"MA Nelson","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"pone.0342085.ref018","doi-asserted-by":"crossref","first-page":"797092","DOI":"10.3389\/fonc.2021.797092","article-title":"Prospects of Immunotherapy for Triple-Negative Breast Cancer","volume":"11","author":"D Qiu","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"pone.0342085.ref019","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group","volume":"7","author":"K El Bairi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"pone.0342085.ref020","doi-asserted-by":"crossref","first-page":"103773","DOI":"10.1016\/j.critrevonc.2022.103773","article-title":"Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review","volume":"177","author":"D Presti","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"pone.0342085.ref021","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/modpathol.2016.109","article-title":"Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group","volume":"29","author":"C Denkert","year":"2016","journal-title":"Mod Pathol"},{"issue":"1","key":"pone.0342085.ref022","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1186\/s12885-024-12962-8","article-title":"Automated scoring methods for quantitative interpretation of Tumour infiltrating lymphocytes (TILs) in breast cancer: a systematic review","volume":"24","author":"NB Baharun","year":"2024","journal-title":"BMC Cancer"},{"key":"pone.0342085.ref023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2019.05.014","article-title":"Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer","volume":"118","author":"T Ochi","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"pone.0342085.ref024","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/cells10020223","article-title":"Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications","volume":"10","author":"MV Dieci","year":"2021","journal-title":"Cells"},{"issue":"1","key":"pone.0342085.ref025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"C Denkert","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0342085.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement","volume":"4","author":"D Moher","year":"2015","journal-title":"Syst Rev"},{"key":"pone.0342085.ref027","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"pone.0342085.ref028","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"JA Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"22","key":"pone.0342085.ref029","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.3390\/diagnostics13223486","article-title":"A Study on the Factors and Prediction Model of Triple-Negative Breast Cancer for Public Health Promotion","volume":"13","author":"Y-H Nam","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"pone.0342085.ref030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/BCTT.S348060","article-title":"Treatment strategies against triple-negative breast cancer: an updated review","volume":"14","author":"M Maqbool","year":"2022","journal-title":"Breast Cancer Targets Ther"},{"issue":"1","key":"pone.0342085.ref031","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"S Zhu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"pone.0342085.ref032","first-page":"153303382211452","article-title":"Molecular classification, treatment, and genetic biomarkers in triple-negative breast cancer: a review","volume":"22","author":"B Lu","year":"2023","journal-title":"Technology In Cancer Research & Treatment"},{"issue":"6","key":"pone.0342085.ref033","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple\u2011negative breast cancer therapy: Current and future perspectives (Review)","volume":"57","author":"K-A Won","year":"2020","journal-title":"Int J Oncol"},{"issue":"7","key":"pone.0342085.ref034","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers","volume":"37","author":"S Loi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"13","key":"pone.0342085.ref035","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"RA Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"pone.0342085.ref036","doi-asserted-by":"crossref","first-page":"910976","DOI":"10.3389\/fonc.2022.910976","article-title":"Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer","volume":"12","author":"CA Huertas-Caro","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"pone.0342085.ref037","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook","volume":"15","author":"O Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"pone.0342085.ref038","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Y Liu","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"pone.0342085.ref039","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"L Yin","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"10","key":"pone.0342085.ref040","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","article-title":"The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition","volume":"32","author":"S Loi","year":"2021","journal-title":"Ann Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:31:35Z","timestamp":1778607095000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342085"}},"subtitle":[],"editor":[{"given":"Julie","family":"Decock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342085","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}